## **ABSTRACT**

## IDENTIFICATION OF POTENTIAL DRUG DRUG INTERACTIONS IN ORAL CARDIOVASCULAR MEDICATION USING MEDSCAPE AT HOSPITAL "X" FROM JANUARY 2023 – JUNE 2023

## Bilgis Fatmalia Andini

Cardiovascular systems consist of the heart and blood vessels (veins, arteries, capillaries) throughout the whole body, thus cardiovascular disease can be defined as any form of disorders that occurs in these organs. Data given by the WHO in 2019, around 17,9 billion people died from CVD and the number continues to increase. This study was purposed to determine the incidence of interactions, the severity of interactions, and the mechanism of interactions that may occur in the prescription of oral cardiovascular drugs at X hospital in Surabaya. This was a descriptive research with restrospective data collected on January to June 2023. Random sampling was used to collect the data. From 91 prescription samples obtained, 86,81% had DDI potential, with 259 interaction found. A total of 81,85% identified as significant severity, while 10,42% identified as serious severity, and 7,72% as minor, and no contraindicated interaction found. A total of 64,86% interaction identified as phamacodynamic interaction, while 19,31% was a pharmacokinetic interaction, and 15,83% interaction found with unknown mechanism. The majority of clinical manifestations that might occur were an increased risk of hyperkalemia. The potential DDI found in this study are theoretical. However, prevention and education should be considered for patients with DDI. The results of this study can be used as a reminder for fellow pharmacist during screening of prescription to prevent the possibility of drug interaction that are detrimental to patients.

**Keywords**: drug interaction, cardiovascular medication, interaction, severity